The cannabis landscape is continuously evolving both nationally and globally. Projections – drawn from Veriheal’s database of 1.75 million users – suggest continued growth in the medical cannabis market.
Our report explores six years of data, including usage patterns, cannabis consumer preferences, and industry trends, providing valuable insights into potential benefits and changing attitudes in the U.S. and worldwide.
An increasing number of consumption methods are entering the growing cannabis market throughout the United States, ranging from cannabis flower and edibles to concentrates and tinctures. As public opinion shifts, regulations shift, allowing for a change in accessibility and awareness around cannabis.
To better understand the relationship between generations and cannabis consumption methods, Veriheal surveyed a sample of over 200,000 adult medical cannabis patients in the U.S. that registered on the Veriheal database between December 10, 2021, and December 10, 2022. Respondents answered questions regarding product preferences, user experience, medical conditions, and several other variables that inform and impact their cannabis use.
There are a variety of products available for consumption on the legal cannabis market. From concentrates to edibles, there are an increasing number of consumption methods to choose from.
At Veriheal we surveyed patients that used our services to better understand the relationship between sex assigned at birth and consumption methods.
Responses from a nationwide cohort of cannabis patients are used to draw connections between cannabis use in women and their preference for edibles. Supporting research is also assessed in order to evaluate the validity of these claims.
Following the spike in cannabis demand throughout the global pandemic, Veriheal’s intelligence team is investigating how patients desired outcomes with cannabis changed throughout. Using the intelligence that spans several years and several groups of mmj patients across the country, our data team is exploring questions like:
What is the impact of COVID-19 on medical marijuana recommendations?
How did patients’ desired outcomes change at a national level and a state level?
Did changes occur among representative populations of U.S. cannabis customers and mmj patients with certain conditions in 2020 and into 2021?
The statements made regarding cannabis products on this website have not been evaluated by the Food and Drug Administration (FDA). Cannabis is not an FDA-approved substance and is still illegal under federal law. The information provided on this website is intended for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It is not intended as medical advice and should not be considered as a substitute for advice from a healthcare professional. We strongly recommend that you consult with a physician or other qualified healthcare provider before using any cannabis products. The use of any information provided on this website is solely at your own risk.